Medical Innovation Exchange

Altimmune sees phase 1 success in tricky NASH indication with GLP-1 agonist

https://www.fiercebiotech.com/biotech/altimmunes-phase-1b-nash-trial-meets-target-though-stock-takes-hit

Leave a Comment

Your email address will not be published.

Leave the field below empty!